Antibiotics for Suspected Urinary Tract Infection
For women with suspected uncomplicated cystitis, first-line treatment should be fosfomycin trometamol 3g single dose, nitrofurantoin 100mg twice daily for 5 days, or pivmecillinam 400mg three times daily for 3-5 days 1, 2.
Treatment Algorithm by Clinical Scenario
Uncomplicated Cystitis in Women
The 2024 European Association of Urology guidelines provide clear first-line options 1:
First-line agents:
- Fosfomycin trometamol: 3g single dose (most convenient, minimal resistance)
- Nitrofurantoin: 100mg twice daily for 5 days (narrow spectrum, stable resistance for 50 years)
- Pivmecillinam: 400mg three times daily for 3-5 days
Alternative agents (use only if local E. coli resistance <20%):
- Cephalosporins (e.g., cefadroxil 500mg twice daily for 3 days)
- Trimethoprim 200mg twice daily for 5 days (avoid first trimester pregnancy)
- Trimethoprim-sulfamethoxazole 160/800mg twice daily for 3 days (avoid last trimester pregnancy)
Critical Decision Point: Mild-Moderate Symptoms
For women with mild-moderate symptoms, symptomatic treatment with ibuprofen alone may be considered as an alternative to antibiotics 1. This approach acknowledges that uncomplicated UTI progresses to pyelonephritis in only 1-2% of cases 3. However, this requires shared decision-making with the patient and close follow-up.
UTI in Men
Men require longer treatment duration: Trimethoprim-sulfamethoxazole 160/800mg twice daily for 7 days, or fluoroquinolones based on local susceptibility 1. If fever is present and acute bacterial prostatitis is suspected, extend treatment to 10-14 days 4.
Uncomplicated Pyelonephritis (Outpatient)
Oral empiric therapy 1:
- Ciprofloxacin 500-750mg twice daily for 7 days
- Levofloxacin 750mg daily for 5 days
- Trimethoprim-sulfamethoxazole 160/800mg twice daily for 14 days (only if fluoroquinolone resistance <10%)
Important caveat: Avoid nitrofurantoin, fosfomycin, and pivmecillinam for pyelonephritis—insufficient efficacy data 1.
Uncomplicated Pyelonephritis (Inpatient/Severe)
Initial IV therapy 1:
- Ciprofloxacin 400mg IV twice daily
- Levofloxacin 750mg IV daily
- Ceftriaxone 1-2g IV daily
- Piperacillin/tazobactam 2.5-4.5g IV three times daily
Reserve carbapenems and novel agents (ceftolozane/tazobactam, ceftazidime/avibactam) for culture-confirmed multidrug-resistant organisms 1.
Key Principles and Common Pitfalls
When NOT to Treat
Do not treat asymptomatic bacteriuria in non-pregnant women, even those with recurrent UTI history 2. Treatment of asymptomatic bacteriuria increases symptomatic recurrence risk (47% vs 13%; RR 3.17) and promotes antibiotic resistance 2. The only exceptions are pregnant women and patients undergoing invasive urologic procedures with mucosal breach 1.
Diagnostic Considerations
Urine culture is NOT routinely needed for typical uncomplicated cystitis symptoms 1. Reserve cultures for:
- Suspected pyelonephritis
- Symptoms not resolving or recurring within 4 weeks
- Atypical symptoms
- Pregnant women
Antibiotic Stewardship
The guidelines strongly emphasize avoiding fluoroquinolones and trimethoprim-sulfamethoxazole as first-line agents due to increasing resistance and collateral damage to normal flora 2, 3. Fluoroquinolones should be reserved for pyelonephritis or when first-line agents fail 5, 6.
Duration Considerations
Recent evidence supports shorter courses for complicated UTI: 5-7 days of fluoroquinolones or 7 days of non-fluoroquinolones is sufficient for most complicated UTIs, even with associated bacteremia 4. The exception remains men with suspected prostatitis (10-14 days needed).
Treatment Failure
If symptoms persist after treatment completion or recur within 2 weeks, obtain urine culture and assume the organism is resistant to the initial agent. Retreat with a 7-day course of a different antibiotic 1.
Strength of Evidence
These recommendations are based on the most recent (2024-2025) high-quality guidelines from the European Association of Urology 1 and AUA/CUA/SUFU 2, representing the strongest available evidence. The emphasis on narrow-spectrum agents (fosfomycin, nitrofurantoin, pivmecillinam) reflects both efficacy data and critical antimicrobial stewardship principles to preserve broader agents for resistant infections.